CONTEXT: The efficacy of antidepressant drug treatment in depression is unsatisfactory; 1 in 3 patients does not fully recover even after several treatment trials. Genetic factors and clinical characteristics contribute to the failure of a favorable treatment outcome. OBJECTIVE: To identify genetic and clinical determinants of antidepressant drug treatment outcome in depression. DESIGN: Genomewide pharmacogenetic association study with 2 independent replication samples. SETTING: We performed a genomewide association study in patients from the Munich Antidepressant Response Signature (MARS) project and in pooled DNA from an independent German replication sample. A set of 328 single-nucleotide polymorphisms highly related to outcome in both genomewide association studies was genotyped in a sample of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. PARTICIPANTS: A total of 339 inpatients with a depressive episode (MARS sample), a further 361 inpatients with depression (German replication sample), and 832 outpatients with major depression (STAR*D sample). MAIN OUTCOME MEASURES: We generated a multilocus genetic variable that described the individual number of alleles of the selected single nucleotide polymorphisms associated with beneficial treatment outcome in the MARS sample ("response" alleles) to evaluate additive genetic effects on antidepressant drug treatment outcome. RESULTS: Multilocus analysis revealed a significant contribution of a binary variable that categorized patients as carriers of a high vs low number of response alleles in the prediction of antidepressant drug treatment outcome in both samples (MARS and STAR*D). In addition, we observed that patients with a comorbid anxiety disorder combined with a low number of response alleles showed the least favorable outcome. CONCLUSION: These results demonstrate the importance of multiple genetic factors combined with clinical features in the prediction of antidepressant drug treatment outcome, which underscores the multifactorial nature of this trait.
CONTEXT: The efficacy of antidepressant drug treatment in depression is unsatisfactory; 1 in 3 patients does not fully recover even after several treatment trials. Genetic factors and clinical characteristics contribute to the failure of a favorable treatment outcome. OBJECTIVE: To identify genetic and clinical determinants of antidepressant drug treatment outcome in depression. DESIGN: Genomewide pharmacogenetic association study with 2 independent replication samples. SETTING: We performed a genomewide association study in patients from the Munich Antidepressant Response Signature (MARS) project and in pooled DNA from an independent German replication sample. A set of 328 single-nucleotide polymorphisms highly related to outcome in both genomewide association studies was genotyped in a sample of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. PARTICIPANTS: A total of 339 inpatients with a depressive episode (MARS sample), a further 361 inpatients with depression (German replication sample), and 832 outpatients with major depression (STAR*D sample). MAIN OUTCOME MEASURES: We generated a multilocus genetic variable that described the individual number of alleles of the selected single nucleotide polymorphisms associated with beneficial treatment outcome in the MARS sample ("response" alleles) to evaluate additive genetic effects on antidepressant drug treatment outcome. RESULTS: Multilocus analysis revealed a significant contribution of a binary variable that categorized patients as carriers of a high vs low number of response alleles in the prediction of antidepressant drug treatment outcome in both samples (MARS and STAR*D). In addition, we observed that patients with a comorbid anxiety disorder combined with a low number of response alleles showed the least favorable outcome. CONCLUSION: These results demonstrate the importance of multiple genetic factors combined with clinical features in the prediction of antidepressant drug treatment outcome, which underscores the multifactorial nature of this trait.
Authors: Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava Journal: Am J Psychiatry Date: 2006-01 Impact factor: 18.112
Authors: Iris Bertram; Hans-Gert Bernstein; Uwe Lendeckel; Alicja Bukowska; Henrik Dobrowolny; Gerburg Keilhoff; Dimitrios Kanakis; Christian Mawrin; Hendrik Bielau; Peter Falkai; Bernhard Bogerts Journal: Ann N Y Acad Sci Date: 2007-01 Impact factor: 5.691
Authors: Magnus Lekman; Gonzalo Laje; Dennis Charney; A John Rush; Alexander F Wilson; Alexa J M Sorant; Robert Lipsky; Stephen R Wisniewski; Husseini Manji; Francis J McMahon; Silvia Paddock Journal: Biol Psychiatry Date: 2008-01-11 Impact factor: 13.382
Authors: Stuart Macgregor; Zhen Zhen Zhao; Anjali Henders; Martin G Nicholas; Grant W Montgomery; Peter M Visscher Journal: Nucleic Acids Res Date: 2008-02-14 Impact factor: 16.971
Authors: Claudia Ditzen; Ning Tang; Archana M Jastorff; Larysa Teplytska; Alexander Yassouridis; Giuseppina Maccarrone; Manfred Uhr; Thomas Bronisch; Christine A Miller; Florian Holsboer; Christoph W Turck Journal: Neuropsychopharmacology Date: 2011-12-14 Impact factor: 7.853
Authors: Colm O'Dushlaine; Stephan Ripke; Douglas M Ruderfer; Steven P Hamilton; Maurizio Fava; Dan V Iosifescu; Isaac S Kohane; Susanne E Churchill; Victor M Castro; Caitlin C Clements; Sarah R Blumenthal; Shawn N Murphy; Jordan W Smoller; Roy H Perlis Journal: Biol Psychiatry Date: 2014-01-19 Impact factor: 13.382
Authors: Karim Malki; Maria Grazia Tosto; Héctor Mouriño-Talín; Sabela Rodríguez-Lorenzo; Oliver Pain; Irfan Jumhaboy; Tina Liu; Panos Parpas; Stuart Newman; Artem Malykh; Lucia Carboni; Rudolf Uher; Peter McGuffin; Leonard C Schalkwyk; Kevin Bryson; Mark Herbster Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2016-10-01 Impact factor: 3.568